ETON

#2087
Eton Pharmaceuticals, Inc. - Common Stock
61.3 1 USD
-0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
61.31
61.81
Jahresspanne
14.27
66.37
Tagesänderung
-1.05%
Monatliche Änderung
+35.97%
6 month change
+247.96%
Jahresänderung
+250.14%
Vorheriger Schlusskurs
61.9 6
Open
61.6 6
Tief
61.3 1
Hoch
61.8 1
Volumen
174
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Eton Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Eton Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Eton Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Eton Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Eton Pharmaceuticals, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K

Eton Pharmaceuticals, Inc. current report, Q3 FY2026

Full document

Eton Pharmaceuticals, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Eton Pharmaceuticals, Inc. on July 31, 2026. The filing discloses the entry into a material definitive agreement and the completion of an asset acquisition in the form of a license for a late-stage rare disease product candidate.

Key Financial Metrics and Transaction Terms

The filing details a license agreement for ASN-001 (timolol topical gel) from Auson Pharmaceuticals Inc. for the treatment of proliferating superficial infantile hemangiomas. Key financial terms include:

  • Upfront Payment: $3.0 million due within thirty days of the agreement.
  • Regulatory Milestone: No specific payment listed for FDA approval alone; payments are tied to commercial sales.
  • Sales Milestones:
    • $5.0 million upon first commercial sale.
    • $1.0 million upon reaching $20.0 million in annual net sales.
    • $2.5 million upon reaching $40.0 million in annual net sales.
    • $5.0 million upon reaching $80.0 million in annual net sales.
    • $10.0 million upon reaching $150.0 million in annual net sales.
    • $10.0 million upon reaching $280.0 million in annual net sales.
  • Royalties: Tiered rates of 10% (up to $200M sales), 13% ($200M-$400M), and 15% (over $400M) based on cumulative lifetime net product sales.

The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for the Company.

Material Changes and Outlook

The primary material change is the acquisition of rights to ASN-001. The Company intends to conduct a bioavailability bridging study and, if successful, submit a New Drug Application (NDA) in the second half of 2027. No other financial changes or guidance were provided in this specific filing.

Risks and Contingencies

Future payments are contingent upon the successful completion of a bioavailability bridging study, FDA approval, and the achievement of specific commercial sales thresholds. The filing does not explicitly list other risks or contingencies beyond the conditional nature of the milestone payments.

Investor Verification Checklist

  • Verify the Company's current cash position to confirm ability to fund the $3.0 million upfront payment.
  • Review the status of the ASN-001 bioavailability bridging study and the timeline for the anticipated 2027 NDA submission.
  • Assess the competitive landscape for treatments of proliferating superficial infantile hemangiomas.
  • Confirm the total potential liability for milestone payments and royalties against projected sales scenarios.

Nachrichten